SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
SciSparc Ltd., through its subsidiary NeuroThera Labs, has launched a Phase IIb clinical trial of SCI-110, a cannabinoid-based drug candidate for Tourette Syndrome treatment, at Yale Child Study Center in the USA. This multinational trial also includes sites in Germany and Israel and builds on positive Phase IIa results, aiming to advance regulator…